Literature DB >> 2830096

The role of cyclic nucleotides in atrial natriuretic peptide-mediated inhibition of aldosterone secretion.

P Q Barrett1, C M Isales.   

Abstract

Using freshly isolated bovine adrenal glomerulosa cells we examined the inhibitory effect of atrial natriuretic peptide (ANP) on aldosterone secretion stimulated by agonists that use either the Ca2+-phosphoinositide or cAMP messenger system. In a continuous perifusion system, angiotensin II (AII) induces a prompt initial rise in aldosterone secretion, followed by a sustained secretory response. Both phases of secretion are rapidly and independently inhibited by ANP. The role of two cyclic nucleotides, cGMP and cAMP, as mediators of this ANP-induced inhibition was examined. The effect of 8-bromo-cGMP (1-100 microM) or (Bu)2cGMP (1-50 microM) on the AII-stimulated rate of secretion was studied in a perifusion system. Either analog, whether added early or late, maximally inhibited by 20-30% only the late or sustained phase of aldosterone secretion. The effect of ANP on cellular cAMP content was examined in a static incubation system. Although ANP caused a reduction in the cAMP content of cells stimulated with either AII or ACTH, it had little or no effect on the cAMP levels in cells stimulated with carbachol. In AII- and ACTH-stimulated cells, the relationship between reduced cAMP content and reduced secretion was explored. In the AII-stimulated cell inhibited by ANP, simple restoration of cAMP content with forskolin did not restore the secretory rate. Pertussis toxin treatment blocked the inhibitory effect of ANP on cAMP content, but did not block its inhibition of secretion. In the ACTH-stimulated cell, reversal of the ANP-induced reduction of cAMP with forskolin, partially restored the stimulated rate of secretion, although restoration of cAMP with a 10-fold higher dose of ACTH did not restore the stimulated rate of secretion in the presence of ANP. These results imply that both the ANP-induced rise in cGMP and the ANP-induced decrease in cellular cAMP content may contribute to the inhibition of steroidogenesis. However, these inhibitory messages do not induce either the magnitude or the temporal pattern of inhibition induced by ANP. Thus, in the adrenal multiple messenger systems may underlie the action of ANP.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2830096     DOI: 10.1210/endo-122-3-799

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  6 in total

1.  Decreased renal corin expression contributes to sodium retention in proteinuric kidney diseases.

Authors:  Danny Polzin; Henriette J Kaminski; Christian Kastner; Wei Wang; Stephanie Krämer; Stepan Gambaryan; Michael Russwurm; Harm Peters; Qingyu Wu; Alain Vandewalle; Sebastian Bachmann; Franziska Theilig
Journal:  Kidney Int       Date:  2010-07-07       Impact factor: 10.612

2.  The presence of atrial-natriuretic-factor receptors of ANF-R2 subtype in rat platelets. Coupling to adenylate cyclase/cyclic AMP signal-transduction system.

Authors:  M B Anand-Srivastava; J Gutkowska; M Cantin
Journal:  Biochem J       Date:  1991-08-15       Impact factor: 3.857

3.  Natriuretic peptides inhibit adenylyl cyclase activity in dispersed eel gill cells.

Authors:  W Callahan; S Nankervis; T Toop
Journal:  J Comp Physiol B       Date:  2004-02-04       Impact factor: 2.200

4.  Characterization of ANF-R2 receptor-mediated inhibition of adenylate cyclase.

Authors:  M B Anand-Srivastava
Journal:  Mol Cell Biochem       Date:  1992-07-06       Impact factor: 3.396

Review 5.  Molecular and genetic aspects of guanylyl cyclase natriuretic peptide receptor-A in regulation of blood pressure and renal function.

Authors:  Kailash N Pandey
Journal:  Physiol Genomics       Date:  2018-08-31       Impact factor: 3.107

6.  Atrial natriuretic factor inhibits metoclopramide stimulated aldosterone release in man.

Authors:  C C Lang; A R Rahman; A D Struthers
Journal:  Br J Clin Pharmacol       Date:  1991-07       Impact factor: 4.335

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.